957 related articles for article (PubMed ID: 18042596)
21. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
22. Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis.
Pascual-Ramos V; Duarte-Rojo A; Villa AR; Hernández-Cruz B; Alarcón-Segovia D; Alcocer-Varela J; Robles-Díaz G
J Rheumatol; 2004 Apr; 31(4):707-12. PubMed ID: 15088295
[TBL] [Abstract][Full Text] [Related]
23. Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus.
Johansson M; Arlestig L; Möller B; Rantapää-Dahlqvist S
Arthritis Rheum; 2005 Jun; 52(6):1665-9. PubMed ID: 15934088
[TBL] [Abstract][Full Text] [Related]
24. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
25. Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement.
Brunner HI; Feldman BM; Urowitz MB; Gladman DD
J Rheumatol; 2003 Feb; 30(2):292-7. PubMed ID: 12563683
[TBL] [Abstract][Full Text] [Related]
26. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
27. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.
Ibañez D; Urowitz MB; Gladman DD
J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601
[TBL] [Abstract][Full Text] [Related]
28. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study.
Appenzeller S; Pereira DA; Costallat LT
Lupus; 2008 Nov; 17(11):1023-8. PubMed ID: 18852227
[TBL] [Abstract][Full Text] [Related]
29. Clinical and serologic factors associated with lupus pleuritis.
Mittoo S; Gelber AC; Hitchon CA; Silverman ED; Pope JE; Fortin PR; Pineau C; Smith CD; Arbillaga H; Gladman DD; Urowitz MB; Zummer M; Clarke AE; Bernatsky S; Hudson M; Tucker LB; Petty RE; ; Peschken CA
J Rheumatol; 2010 Apr; 37(4):747-53. PubMed ID: 20110526
[TBL] [Abstract][Full Text] [Related]
30. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
31. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
Ibañez D; Gladman DD; Urowitz MB
J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616
[TBL] [Abstract][Full Text] [Related]
32. Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan.
Rabbani MA; Habib HB; Islam M; Ahmad B; Shah SM; Tahir S; Merchant D; Ahmad A
Lupus; 2010 Nov; 19(13):1573-8. PubMed ID: 20705644
[TBL] [Abstract][Full Text] [Related]
33. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
Ward MM; Pyun E; Studenski S
Arch Intern Med; 1996 Jun; 156(12):1337-44. PubMed ID: 8651844
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
35. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
36. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
37. Cigarette smoking and cutaneous damage in systemic lupus erythematosus.
Turchin I; Bernatsky S; Clarke AE; St-Pierre Y; Pineau CA
J Rheumatol; 2009 Dec; 36(12):2691-3. PubMed ID: 19884279
[TBL] [Abstract][Full Text] [Related]
38. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis.
Nossent JC
J Rheumatol; 1998 Apr; 25(4):654-9. PubMed ID: 9558165
[TBL] [Abstract][Full Text] [Related]
39. [Significance of damage index in predicting systemic lupus erythematosus outcome].
Tarasova IA; Ivanova MM; Zhorniak AP; Nasonova VA
Ter Arkh; 2003; 75(1):59-62. PubMed ID: 12652960
[TBL] [Abstract][Full Text] [Related]
40. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.
Lopez R; Davidson JE; Beeby MD; Egger PJ; Isenberg DA
Rheumatology (Oxford); 2012 Mar; 51(3):491-8. PubMed ID: 22109798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
